Wei Li

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

Zefei Jiang, Wei Li, Xichun Hu et al. · The Lancet Oncology · 2019 · 261 citations

Breast Oncology, Medicine, Pharmacology +8

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Jianming Xu, Yi Li, Qingxia Fan et al. · Nature Communications · 2022 · 147 citations · Full text

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study

Yi‐Long Wu, Li Zhang, Yun Fan et al. · International Journal of Cancer · 2020 · 93 citations · Full text

Randomized Clinical Trial, Health Sciences, Medicine +13

Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial

Peng Yuan, Xichun Hu, Tao Sun et al. · European Journal of Cancer · 2019 · 86 citations

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study

Binghe Xu, Wei Li, Qingyuan Zhang et al. · Breast Cancer Research and Treatment · 2020 · 46 citations · Full text